Page 19 - Biocon

Market Ahead, May 11: Top factors that could guide markets this week

Around 50 companies including the likes of Maruti Suzuki, Nestle, Dr Reddy's Labs, Biocon, and Bandhan Bank are scheduled to announce their March quarter results.

Mumbai docs try Biocon and Roche's biologic drugs on critical Covid cases

Two repurposed drugs for rheumatoid arthritis and psoriasis are being tried on over 100 patients in Mumbai

MSCI India rebalancing to stoke FPI inflows to the tune of Rs 1,900 cr

The rebalancing is scheduled to take place on May 12 and the changes will become effective from June 1

India Inc wants govt to shift focus to economy amid Covid-19 outbreak

CEOs warn of economic depression, say need to work within new normal

Biocon gains 5% as two Bengaluru facilities receive EIR from USFDA

The stock was trading close to its all-time high level of Rs 359, touched in September 2018

Biocon, Mylan launch Fulphila, a biosimilar Pegfilgrastim in Australia

CEO of Biocon Biologics, Dr Christiane Hamacher said, Fulphila, co-developed by Biocon Biologics and Mylan, is the third biosimilar to be commercialised in Australia

Malaysia plant boosts Biocon prospects in US and other key markets

Firm seen benefiting from operating leverage, biologic sales by FY22

Biocon's US prospects get a boost after company receives EIR from USFDA

The insulin patent win, clearance of Malaysian unit and oncology biosimilar filing are triggers

Biocon gains 5% as manufacturing unit in Malaysia gets EIR from USFDA

Biocon Sdn Bhd, a subsidiary of Biocon, received the EIR from the USFDA for the pre-approval inspection of its insulin manufacturing facility in Malaysia, for insulin glargine

Build to last

In the second part of a series, the author notes down some lessons for start-ups

Biocon: Fresh biosimilar opportunities to give a boost to its US prospects

The insulin patent win and filing of another oncology biosimilar in the US to drive earnings

Biocon receives EIR from USFDA for good manufacturing practice inspection

"We remain committed to global standards of quality and compliance," company spokesperson said

Biocon, Mylan win patent case for insulin device against Sanofi in US

Development takes Biocon a step closer to commercialise its glargine biosimilar Semglee in America

Biocon partner's Cancer drug licence application gets USFDA approval

The application sought approval of Mylan's drug for treatment of patients with metastatic colorectal cancer with fluorouracil-based chemotherapy

USFDA accepts Biocon-Mylan's Avastin biosimilar application for review

The application seeks approval of biosimilar bevacizumab for treatment of patients with metastatic colorectal cancer in addition to other ailments

USFDA accepts proposed biosimilar application by Mylan, Biocon for review

The application seeks approval of Bevacizumab for the first-line and second-line treatment of patients with metastatic colorectal cancer in combination with fluorouracil-based chemotherapy

Biocon gets two observations from USFDA for Bengaluru-based API plant

Biocon shares on Thurday ended 0.17 per cent up at Rs 299.20 apiece on the BSE.

Biocon hits 52-wk high as Malaysian unit gets 3 observations from US FDA

The stock of India's biggest biotechnology company was trading higher for the third straight day, and has surpassed it's previous high of Rs 321 touched on February 15, 2019 in the intra-day trade.

Biocon gets 3 observations from US health regulator for Malaysia facility

The FDA has set a target action date for its Insulin Glargine application in June 2020

Kiran Mazumdar-Shaw wins EY Entrepreneur of the Year award for 2019

Awards announced for nine other categories; Adi Godrej gets Lifetime achievement award